Most people begin noticing appetite reduction at the 2mg dose (weeks 5-8) and visible weight loss by weeks 8-12
Individual factors age, overall health, medications, and tolerance also influence how any bioactive compound is handled by the body, yet none of these interactions have been characterized for BPC-157 in humans
Oral contraceptives: may reduce plasma concentrations of valproate
Impaired cell migration, as a critical factor, affects diabetic wound healing during the proliferative and remodeling phases
Moreover, it is known to enhance AR transactivation in low androgen environments (Orio et al., 2002)
Si no se observa mejora transcurridos 9-12 meses, el suspender el tto